DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR CUBICIN RF
» See Plans and Pricing
All Clinical Trials for Cubicin Rf
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00295178 | Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas | Completed | Cubist Pharmaceuticals LLC | Phase 4 | 2006-02-01 | This study is designed to investigate the difference in speed and degree of symptom resolution between daptomycin and vancomycin in subjects treated for cellulitis or erysipelas by evaluation of the following parameters: - Time to erythema margin cessation to progress - Time to defervescence - Time to hospital discharge following relief of the presenting cellulitis or erysipelas - Degree of improvement of the following signs and symptom of cellulitis or erysipelas including - Degree of improvement of cellulitis-related pain and swelling as reported by subjects Additionally, the difference in frequency of Adverse Events between daptomycin and vancomycin will be described. |
| NCT00638157 | Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE) | Terminated | Cubist Pharmaceuticals LLC | Phase 4 | 2008-03-01 | multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the treatment of SAIE |
| NCT00651131 | Cubicin(R) for Complicated Post-Surgical Wound Infections | Terminated | Cubist Pharmaceuticals LLC | Phase 4 | 2004-06-01 | The purpose of the study is to describe the clinical efficacy of CUBICIN therapy in patients with superficial and deep post-surgical Gram-positive wound infections |
| NCT00772447 | China Registration Study in Patients With Skin Infections | Completed | AstraZeneca | Phase 3 | 2008-09-01 | The objectives of this study is to evaluate the Safety and Efficacy of Intravenous Daptomycin (Cubicin®)Compared with that of Comparator (Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-cloxacillin) in the Treatment of Chinese Subjects with Complicated Bacterial Skin and Skin Structure Infection due to Gram-Positive Pathogens. |
| NCT01012089 | Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease | Completed | Cubist Pharmaceuticals LLC | N/A | 2009-11-01 | The purpose of this study is to: 1. Study the pharmacokinetics and safety of daptomycin in children on hemodialysis (HD) and peritoneal dialysis (PD). 2. Determine urine, HD and PD clearance of daptomycin. |
| NCT01012089 | Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease | Completed | University of Oklahoma | N/A | 2009-11-01 | The purpose of this study is to: 1. Study the pharmacokinetics and safety of daptomycin in children on hemodialysis (HD) and peritoneal dialysis (PD). 2. Determine urine, HD and PD clearance of daptomycin. |
| NCT01175707 | Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting | Terminated | Cubist Pharmaceuticals LLC | Phase 4 | 2010-07-01 | This is a randomized, open-label, multi-center, phase 4 study designed to compare intravenous (IV) daptomycin and IV vancomycin administered in a home infusion setting for the treatment of complicated skin and skin structure infections (cSSSI) due to Gram-positive bacteria in participants who are prescribed vancomycin for 7 to 14 days and who are planning to receive vancomycin in a home-infusion setting. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Cubicin Rf
Condition Name
Condition MeSH
Clinical Trial Locations for Cubicin Rf
Trials by Country
Clinical Trial Progress for Cubicin Rf
Clinical Trial Phase
Clinical Trial Sponsors for Cubicin Rf
Sponsor Name
